Bioactive phytochemicals
AssigneePhytoquest Limited
InventorRobert James Nash
Life of this patent
Estimating the term…
Abstract
Described are processes for the production of a composition comprising (2R, 3R, 4R, 5S)-3, 4, 5-trihydroxypiperidine-2-carboxylic acid (idoBR1), said process comprising the steps of: a) providing plant material from a botanical source comprising plant of the family Cucurbitaceae; b) fractionating said plant material to produce an extract enriched in idoBR1 c) assaying said extract for: i) inhibitory activity against sialidase or TNF-alpha or ii) IL-10 stimulatory activity; and d) formulating said assayed extract with a cosmetically-, nutraceutically- or pharmaceutically-acceptable excipient or carrier to produce a cosmetic, nutraceutical or pharmaceutical composition.
Claims26
A process for the production of a composition comprising (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid (idoBR1), said process comprising the steps of:
- (e) providing plant material from a botanical source comprising plants of the the family Cucurbitaceae;
- (f) fractionating said plant material to produce an extract enriched in idoBR1;
- (g) assaying said extract for:
- (i) inhibitory activity against sialidase;
- (ii) inhibitory activity against TNF-alpha;
- or (iii) IL-10 stimulatory activity;
- and
- (h) formulating said assayed extract with a cosmetically-, nutraceutically- or pharmaceutically-acceptable excipient or carrier to produce a cosmetic, nutraceutical or pharmaceutical composition.
-16. (canceled)
-23. (canceled)
-31. (canceled)
-36. (canceled)
(canceled)
A method for monitoring the quality of a cosmetic, nutraceutical or pharmaceutical composition comprising the steps of:
- (a) providing a sample of the composition;
- and (b) assaying said sample for:
- (i) inhibitory activity against sialidase;
- (ii) inhibitory activity against TNF-alpha;
- or (iii) IL-10 stimulatory activity.
-51. (canceled)
A method for treating muscle inflammation comprising administering a pharmaceutical composition comprising idoBR1 and a pharmaceutically acceptable excipient or carrier to a subject in need thereof.
Dependencies are inferred from the claim text.